Pathologic Activation of Thrombopoietin Receptor and JAK2-STAT5 Pathway by Frameshift Mutants of Mouse Calreticulin

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Mar 19

PMID 26987905

Citations 30

Authors

T Balligand

Y Achouri

C Pecquet

I Chachoua

H Nivarthi

C Marty

W Vainchenker

I Plo

R Kralovics

S N Constantinescu

Affiliations

Soon will be listed here.

Citing Articles

Clonal hematopoiesis and hematological malignancy.

Dunn W, McLoughlin M, Vassiliou G J Clin Invest. 2024; 134(19).

PMID: 39352393 PMC: 11444162. DOI: 10.1172/JCI180065.

Platelet function studies in myeloproliferative neoplasms patients with or mutation.

Guy A, Helzy K, Mansier O, Bordet J, Riviere E, Fiore M Res Pract Thromb Haemost. 2023; 7(2):100060.

PMID: 36908768 PMC: 9992751. DOI: 10.1016/j.rpth.2023.100060.

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.

Fosselteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K Leukemia. 2023; 37(4):843-853.

PMID: 36813992 PMC: 10079532. DOI: 10.1038/s41375-023-01848-6.

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.

Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G Blood. 2022; 141(8):917-929.

PMID: 36356299 PMC: 10651872. DOI: 10.1182/blood.2022016846.

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.

Morsia E, Torre E, Poloni A, Olivieri A, Rupoli S Int J Mol Sci. 2022; 23(9).

PMID: 35562964 PMC: 9100530. DOI: 10.3390/ijms23094573.

References

Passamonti F, Caramazza D, Maffioli M . JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014; 370(12):1168-9. DOI: 10.1056/NEJMc1400499. View

Kohlhuber F, ROGERS N, Watling D, Feng J, Guschin D, Briscoe J . A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997; 17(2):695-706. PMC: 231795. DOI: 10.1128/MCB.17.2.695. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R, Marty C . Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2015; 127(10):1325-35. DOI: 10.1182/blood-2015-11-681932. View

Michalak M, Corbett E, Mesaeli N, Nakamura K, Opas M . Calreticulin: one protein, one gene, many functions. Biochem J. 1999; 344 Pt 2:281-92. PMC: 1220642. View

Nangalia J, Massie C, Baxter E, Nice F, Gundem G, Wedge D . Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405. PMC: 3966280. DOI: 10.1056/NEJMoa1312542. View

Nivarthi H, Chen D, Cleary C, Kubesova B, Jager R, Bogner E . Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia. 2016; 30(8):1759-63. PMC: 4980558. DOI: 10.1038/leu.2016.32. View

Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E . MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia. 2014; 29(2):494-7. PMC: 4320290. DOI: 10.1038/leu.2014.285. View

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan A, Milosevic J . JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013; 123(10):1544-51. PMC: 3945864. DOI: 10.1182/blood-2013-11-539098. View

10.

Mashiko D, Fujihara Y, Satouh Y, Miyata H, Isotani A, Ikawa M . Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci Rep. 2013; 3:3355. PMC: 3842082. DOI: 10.1038/srep03355. View

11.

Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M . Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2015; 127(10):1317-24. DOI: 10.1182/blood-2015-11-679571. View

12.

Guglielmelli P, Bartalucci N, Rotunno G, Vannucchi A . Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. Expert Rev Hematol. 2014; 7(4):423-5. DOI: 10.1586/17474086.2014.920250. View

13.

Staerk J, Defour J, Pecquet C, Leroy E, Antoine-Poirel H, Brett I . Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 2011; 30(21):4398-413. PMC: 3230373. DOI: 10.1038/emboj.2011.315. View

14.

Cong L, Ran F, Cox D, Lin S, Barretto R, Habib N . Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819-23. PMC: 3795411. DOI: 10.1126/science.1231143. View

15.

Yoshida H, Kondo M, Ichihashi T, Hashimoto N, Inazawa J, Ohno R . A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet. 1997; 100(1):21-4. DOI: 10.1016/s0165-4608(97)00017-4. View